Modern oncological approaches to gastric adenocarcinoma

Gastroenterol Clin North Am. 2013 Jun;42(2):359-69. doi: 10.1016/j.gtc.2013.01.011. Epub 2013 Mar 1.

Abstract

Gastric cancer (GC) is a major health burden throughout the world, especially in certain endemic regions. GC is commonly diagnosed at an advanced stage because of the lack of early detection strategies and is usually associated with a dismal outcome. For patients with localized GC (LGC), surgery is the best cure: cure rates are highly associated with the surgical pathology stage. Adjunctive therapies improve the cure rates by about an additional 10%. Therefore, a multimodality approach is highly recommended for all patients with LGC. This article highlights some of the therapeutic advances made against GC and features important ongoing trials.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / therapy*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemoradiotherapy, Adjuvant
  • Chemotherapy, Adjuvant
  • ErbB Receptors / antagonists & inhibitors
  • Gastrectomy*
  • Humans
  • Molecular Targeted Therapy*
  • Neoadjuvant Therapy
  • Proto-Oncogene Proteins c-met / metabolism
  • Signal Transduction / genetics
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / therapy*
  • Trastuzumab
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • ErbB Receptors
  • Proto-Oncogene Proteins c-met
  • Trastuzumab